Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P2OW
|
|||
| Former ID |
DIB012769
|
|||
| Drug Name |
IR208
|
|||
| Synonyms |
NeuroVax; BV6S2/6S5; IR-208; IR-208); Vbeta6S2/6S5; H-Leu-Gly-Gln-Gly-Pro-Glu-Phe-Leu-Thr-Tyr-Phe-Gln-Asn-Glu-Ala-Gln-Leu-Glu-Lys-Ser-OH
Click to Show/Hide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2/3 | [1] | |
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 2 | [2], [3], [4] | ||
| Company |
Immune response biopharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02057159) A Study of NeuroVax a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.